Matthew Biegler analyst OPPENHEIMER

Currently out of the existing stock ratings of Matthew Biegler, 169 are a BUY (97.69%), 4 are a HOLD (2.31%).

Matthew Biegler

Work Performance Price Targets & Ratings Chart

Analyst Matthew Biegler, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 34.11% that have a potential upside of 48.15% achieved within 146 days.

Matthew Biegler’s has documented 324 price targets and ratings displayed on 30 stocks. The coverage is on Healthcare, Energy, Industrials sectors.

Most recent stock forecast was given on RLAY, Relay Therapeutics at 28-Apr-2026.

Wall Street Analyst Matthew Biegler

Analyst best performing recommendations are on CELU (CELULARITY).
The best stock recommendation documented was for FIX (COMFORT SYSTEMS USA) at 3/16/2020. The price target of $32 was fulfilled within 1 day with a profit of $1.52 (4.99%) receiving and performance score of 49.87.

Average potential price target upside

FATE Fate Therapeutics MRKR Marker Therapeutics TPTX Turning Point Therapeutics ZNTL Zentalis Pharmaceuticals Llc BPMC Blueprint Medicines Corp FIXX Homology Medicines FULC Fulcrum Therapeutics NKTX Nkarta VOR Vor Biopharma CELU Celularity MDNA Medicenna Therapeutics Corp TYRA Tyra Biosciences IDYA Ideaya Biosciences RLAY Relay Therapeutics PRTG Portage Biotech APTO Aptose Biosciences OLMA Olema Pharmaceuticals DAWN Day One Biopharmaceuticals ALLO Allogene Therapeutics ARVN Arvinas ORIC Oric Pharmaceuticals RNAC Cartesian Therapeutics NRIX Nurix Therapeutics AQST Aquestive Therapeutics ACRV Acrivon Therapeutics, Common Stock BP BP PLC ADR CTMX CytomX Therapeutics FIX Comfort Systems USA MD Mednax OKUR OnKure Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 14-Aug-2024

$8

$5.82 (266.97%)

$6

1 months 28 days ago
(14-Aug-2026)

19/26 (73.08%)

$5.43 (211.28%)

264

Hold Since 27-Mar-2023

$3.5

$1.32 (60.55%)

$4

1 months 28 days ago
(14-Aug-2026)

2/4 (50%)

$0.93 (36.19%)

49

Buy Since 04-May-2026

$7

$4.9 (233.33%)

$7

4 months 4 days ago
(08-Jun-2026)

0/7 (0%)

$5.09 (266.49%)

Hold Since 27-Feb-2024

$7

$4.9 (233.33%)

$5

11 months 15 days ago
(27-Oct-2025)

11/16 (68.75%)

$5.45 (351.61%)

142

Buy Since 12-Mar-2020

$7

$4.9 (233.33%)

1 years 1 months 9 days ago
(03-Sep-2025)

1/4 (25%)

$6 (600.00%)

36

Show more analysts

Please expand the browser size to see the chart

Which stock is Matthew Biegler most bullish on?

Potential upside of $0.12 has been obtained for RLAY (RELAY THERAPEUTICS)

What Year was the first public recommendation made by Matthew Biegler?

On 2019
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?